Clinical trials: Acute Liver Injury
Infections, Bacterial
WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Workpackage 2 (WP2) and Workgroup 1.
- Trial name
- NCT01587768
- Testing
- Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
SARS-CoV-2
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
- Trial name
- NCT04447404
- Testing
- DUR-928
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Durect
Acute Liver Failure, Acute Liver Injury, Drug Induced
miroliverELAP® for the Treatment of Acute Liver Failure: A Phase 1 Trial
The clinical trial will assess the safety of miroliverELAP for the treatment of acute liver failure, severe acute alcohol-associated hepatitis, or acute on chronic liver failure.
- Conditions
- Acute Liver Failure, Acute Liver Injury, Drug Induced, Acute on Chronic Liver Failure (ACLF), Acute Alcoholic Hepatitis
- Trial name
- NCT06285253
- Testing
- miroliverELAP treatment
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Miromatrix Medical Inc.
Drug-Induced Liver Injury
Risk of Acute Liver Injury in Users of Antimicrobials
Moxifloxacin is a broad-spectrum antibacterial agent used to treat common community-acquired respiratory tract infections, complicated intra-abdominal infections, and pelvic inflammatory disease.
- Trial name
- NCT01434173
- Testing
- Moxifloxacin (Avelox, BAY12-8039), Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
- Where
- United States
- Volunteers
- 1,299,056 people
- Sponsor
- Bayer
Neoplasms, Liver Injury
Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.
- Trial name
- MAGIC (NCT01802996)
- Testing
- Magnesium Isoglycyrrhizinate Injection
- Where
- 27 sites in China
- Volunteers
- 2,040 people
- Sponsor
- Cttq
Acute Drug Induced Liver Injury
Efficacy and Safety of Polyene Phosphatidylcholine in Treatment of Patients With Acute Drug-induced Liver Injury
The purpose of this study is to explore the efficacy and the safety of polyene phosphatidylcholine Injection in patients with acute drug-induced liver injury after 2-4 weeks of treatment.
- Trial name
- NCT04595916
- Testing
- Polyene phosphatidylcholine injection 930 mg QD, Magnesium Isoglycyrrhizinate injection 200 mg QD
- Where
- 9 sites in China
- Volunteers
- 73 people
- Sponsor
- Sichuan Haisco Pharmaceutical Group Co., Ltd
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Hepatorenal Syndrome, Acute Kidney Injury
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
This study aims to evaluate the safety, tolerability and efficacy of R2R01 combined with terlipressin as compared to terlipressin alone in the treatment of patients with HRS-AKI
- Trial name
- NCT05875948
- Testing
- R2R01, Terlipressin
- Where
- 7 sites in United States
- Volunteers
- 95 people
- Sponsor
- River 2 Renal Corp.
Alcoholic Hepatitis
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe…
- Trial name
- AH (NCT03432260)
- Testing
- DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Durect
Cirrhosis, Ascites
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
OCE-205 is being tested to treat participants who have developed Hepatorenal Syndrome-Acute Kidney Injury as a complication of cirrhosis with ascites.
- Conditions
- Cirrhosis, Ascites, Hepatorenal Syndrome, Acute Kidney Injury
- Trial name
- NCT05309200
- Testing
- OCE-205
- Where
- 23 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Ocelot Bio, Inc
Multiple Myeloma
A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg
1. Planned enrollment period One year (The planned number of patients to be enrolled is set to 400 patients.) Since all patients who are prescribed with Pomalyst are registered in RevMate®, enrollment using the Registration Form…
- Trial name
- NCT02921828
- Where
- 2 sites in United States, Japan
- Volunteers
- 1,149 people
- Sponsor
- Celgene
Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF)
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard…
- Conditions
- Hepatic Encephalopathy, Acute on Chronic Liver Failure (ACLF), Decompensated Cirrhosis
- Trial name
- NCT06987968
- Testing
- VS-01 on top of SOC (Active Treatment Group), SOC
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 3 people
- Sponsor
- Genfit
Hepatorenal Syndrome, Liver Cirrhosis
Endothelin Receptor Antagonism With Ambrisentan to Treat Hepatorenal Syndrome
Patients with advanced cirrhosis of the liver develop kidney problems occasionally. This condition is called Hepatorenal Syndrome, requires hospitalization and frequently results in death.
- Conditions
- Hepatorenal Syndrome, Liver Cirrhosis, Acute Kidney Injury, Ascites Hepatic
- Trial name
- NCT06256432
- Testing
- Ambrisentan, Terlipressin
- Where
- 6 sites in India
- Volunteers
- 54 people
- Sponsor
- Noorik Biopharmaceuticals AG
Acute Liver Failure, Acute-On-Chronic Liver Failure
F573 for Injection for the Treatment of Liver Injury/Failure
This study was a randomized, double-blind, placebo-controlled PhaseⅡ clinical trial . The primary objective of this study was to evaluate the safety of F573 for injection in patients with liver injury (drug-induced liver injury…
- Trial name
- NCT05689645
- Testing
- F573 for injection, Sterilizing water for injection
- Where
- 10 sites in China
- Volunteers
- 97 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Acute Liver Injury
Acute Liver Injury in Patients on Dapagliflozin
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695095
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 424,091 people
- Sponsor
- AstraZeneca
Drug-Induced Liver Injury
Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury
The purpose of this study is to investigate the safety, effective dosage and treatment of Magnesium Isolycyrrhizinate Injection to cure the acute drug-induced liver injury compared with the Tiopronin Injection.
- Trial name
- NCT02734966
- Testing
- Magnesium Isoglycyrrhizinate Injection 100mg OD, Magnesium Isoglycyrrhizinate Injection 200mg OD, Tiopronin Injection
- Where
- 8 sites in China
- Volunteers
- 174 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alcoholic Hepatitis
A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment
This is a randomized, double-blind, placebo-controlled, phase 2b clinical Trial evaluating Safety and Efficacy of DUR-928 (an experimental medication) in Patients with Alcoholic Hepatitis (AH).
- Trial name
- AHFIRM (NCT04563026)
- Testing
- DUR-928 30 mg, DUR-928 90 mg
- Where
- 68 sites in United States, Australia and 4 more
- Volunteers
- 307 people
- Sponsor
- Durect
Multiple Sclerosis, Relapsing-Remitting
A Post-Authorization, Long-term Study of Ozanimod Real-world Safety
The purpose of this study is to determine the rates of adverse events of interest (AEIs) in a real-world population of participants with relapsing remitting multiple sclerosis (RRMS) receiving Ozanimod, sphingosine-1 phosphate…
- Trial name
- ORION (NCT05605782)
- Where
- United States
- Volunteers
- 9,000 people
- Sponsor
- Bristol-Myers Squibb
Bleeding ,Arrhythmias, Heart Failure, Acute Renal Failure, Acute Liver Failure, Dyspnoea, Gout
Extended Drug Utilization Study Among Patients Exposed to Ticagrelor, Clopidogrel and Prasugrel
The purpose of the study is to describe patient characteristics and drug usage among patients that are prescribed ticagrelor for the first time and to compare them with patients who are prescribed clopidogrel and prasugrel for…
- Trial name
- NCT01276275
- Testing
- Risk of selected safety events
- Where
- Sweden
- Volunteers
- 7,200 people
- Sponsor
- AstraZeneca